Journal Watch · Frontiers in Immunology · 2026
Case Report: Ultrasound features of pathological complete response in middle and low rectal cancer with high microsatellite instability after neoadjuvant immunotherapy: a case series.
Ultrasound-guided biopsy may provide complementary diagnostic information for confirming pCR in cases with persistent imaging abnormalities.
TL;DR
Ultrasound-guided biopsy may provide complementary diagnostic information for confirming pCR in cases with persistent imaging abnormalities.
Key findings
- Our preliminary observations suggest that multimodal TRUS features, including reduced lesion size, diminished vascularity, heterogeneous hypoenhancement with non-enhancing areas on contrast-enhanced ultrasound, and reduced stiffness on shear wave elastography, may serve as potential imaging indicators of pCR in patients with MSI-H mid- to low-rectal cancer.
- Ultrasound-guided biopsy may provide complementary diagnostic information for confirming pCR in cases with persistent imaging abnormalities.
What they did
In this case series, we comparatively analyzed multimodal transrectal ultrasound (TRUS) features before and after NIT in three patients with MSI-H mid- to low-rectal cancer. Despite imaging findings suggestive of residual lesions, two patients achieved pCR as confirmed by postoperative pathology, and one patient had no definite atypical components identified on ultrasound-guided biopsy.
Full abstract (original)
Background: Accurate assessment of complete clinical response following neoadjuvant chemoradiotherapy remains challenging, and radiological evaluation criteria established for this treatment modality may not be applicable to neoadjuvant immunotherapy (NIT). Currently, there are no published studies describing the ultrasound features of pathological complete response (pCR) in patients with microsatellite instability-high (MSI-H) rectal cancer following NIT.
What they did: In this case series, we comparatively analyzed multimodal transrectal ultrasound (TRUS) features before and after NIT in three patients with MSI-H mid- to low-rectal cancer. Despite imaging findings suggestive of residual lesions, two patients achieved pCR as confirmed by postoperative pathology, and one patient had no definite atypical components identified on ultrasound-guided biopsy.
Results & conclusions: Our preliminary observations suggest that multimodal TRUS features, including reduced lesion size, diminished vascularity, heterogeneous hypoenhancement with non-enhancing areas on contrast-enhanced ultrasound, and reduced stiffness on shear wave elastography, may serve as potential imaging indicators of pCR in patients with MSI-H mid- to low-rectal cancer. Ultrasound-guided biopsy may provide complementary diagnostic information for confirming pCR in cases with persistent imaging abnormalities.
Abstract © the authors / Frontiers in Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.3389/fimmu.2026.1772953 · PubMed 42051496.
Why it matters for pharma & biotech
- Relevant to Immunology teams tracking Frontiers in Immunology for new targets, mechanisms and biomarkers.
- Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
- The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.
Frequently asked questions
What did this Frontiers in Immunology study find?
Ultrasound-guided biopsy may provide complementary diagnostic information for confirming pCR in cases with persistent imaging abnormalities.
What type of study is this?
It is a case report / series, published in Frontiers in Immunology in 2026. In this case series, we comparatively analyzed multimodal transrectal ultrasound (TRUS) features before and after NIT in three patients with MSI-H mid- to low-rectal cancer.
Where can I read the original paper?
The original is at the publisher via DOI 10.3389/fimmu.2026.1772953. PubMed ID: 42051496. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/case-report-ultrasound-features-of-pathological-complete-response-in-mid-772953/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides